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COST-EFFECTIVENESS OF DRUG ELUTING STENTS FOR
STABLE ANGINA
Kristiansen IS
University of Oslo, Oslo, Norway
OBJECTIVE: The aim of this study was to explore cost and
health consequences of using drug eluting stents (DES) instead
of bare metal stents (BMS) for patients with stable angina.
METHODS: We developed a Markov model which captures
costs and outcomes the ﬁrst two years after PCI with stent for
stable angina. After each PCI, patients can become well, have a
new intervention (PCI og CABG) or die. The model was based
on meta-analyses of trials comparing DES with BMS. These trials
indicate that the use of DES reduces the need for repeat revas-
cularisation by 36% to 86%. We assumed that DES will reduce
mortality because of fewer intervention related deaths, but also
explored a potential increased mortality because the meta-
analysis indicates a non-signiﬁcant trend towards increased 
mortality of DES compared to BMS. One-way and Monte-Carlo
sensitivity analyses were applied. RESULTS: The estimated cost
per avoided reintervention was $5000 when BMS was replaced
by DES, ranging from $200 to $16,000 in one-way sensitivity
analyses. The price of a drug eluting stent would have to be
reduced from currently $2000 to $1400 to make the use of DES
cost saving compared to BMS (current purchasing price $560).
The estimated cost per life year gained and quality adjusted life
year gained were $121,000 and $46,000, respectively, when
increased mortality was disregarded in the model. Probabilistic
sensitivity analysis indicated a 64% probability that drug eluting
stents were cost-effective if society is willing to pay $50,000 for
one quality adjusted life year. When the increased mortality was
included, BMS was the dominant strategy, with both lower costs
and greater life expectancy. CONCLUSIONS: The cost-
effectiveness of DES depended heavily on purchasing price of the
stents and rate of reintervention in routine practice and may not
be cost-effective at current price level.
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IMPACT OF STATIN THERAPY INTENSITY ON ALL-CAUSE
MORTALITY FOLLOWING CARDIOVASCULAR
HOSPITALIZATION IN A MANAGED CARE POPULATION
Fintel DJ1, Joyce A2, Mackell JA3, Graff J3, Kuntze CE3
1Northwestern University, Chicago, IL, USA; 2PharMetrics, Inc,
Stamford, CT, USA; 3Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: To examine if intensive statin therapy beneﬁts
demonstrated in randomized clinical trials (RCTs) could be sub-
stantiated in managed care patients hospitalized for cardiovas-
cular events and procedures (CVEP). METHODS: An integrated
US medical/pharmacy claims database (43 million members) was
used to examine patient mortality risk following hospitalization
discharge for CVEP (nonfatal MI, resuscitated cardiac arrest,
acute coronary occlusion, CABG or PTCA). Inclusion criteria:
age 18 years, health plan enrollment >12 months prior to and
>1 month after hospitalization, and index hospitalization for
CVEP between January 2000 to June 2003. Patients were iden-
tiﬁed as receiving no statin therapy within 30 days after dis-
charge (S-), or receiving statin therapy. Statin therapy was
deﬁned as standard (STD) or intensive (INT), < or >40% LDL-
C lowering efﬁcacy according to the package insert. Patients
were matched (INT vs. S-, STD vs. S-, and INT vs. STD) based
on estimated propensity scores for statin therapy to adjust for
baseline differences. Death was presumed from claims activity
indicating a likely fatal event followed by health plan disenroll-
ment. Mortality was compared among groups using Cox pro-
portional hazards models controlling for prognostic factors.
RESULTS: Among matched pairs, crude death rates were 
3.26% vs. 5.21% for INT vs. S- (n = 1688 matched pairs);
4.39% vs. 5.75% for STD vs. S- (n = 2346 matched pairs); and
2.33% vs. 3.26% for INT vs. STD (n = 3342 matched pairs). In
Cox Proportional hazards models, risk of death was lower
among patients treated with INT and STD therapy vs. S- (INT
vs. S- Hazard Ratio [HR] = 0.581, 95% CI = 0.414, 0.816, p =
0.0017; STD vs. S- HR = 0.677, 95% CI = 0.525, 0.872, p =
0.0026). Patients receiving INT had 30% lower risk of death
compared to STD (HR = 0.707, 95% CI = 0.528, 0.947; p =
0.0200). CONCLUSIONS: This real-world study validates ben-
eﬁts of intensive statin therapy reported in recent RCTs, and 
clinically signiﬁcant reductions in mortality following cardio-
vascular hospitalization.
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COSTS OF DIAGNOSIS OF ARRHYTHMOGENIC RIGTH
VENTRICULAR CARDIOMYOPATHY IN INDIVIDUALS WITH 
A FAMILY HISTORY OF THE DISEASE IN POLAND
Glinka M, Kowalik E,Wlodarska EK,Wozniak O, Hoffman P
Institute of Cardiology, Warsaw, Poland
OBJECTIVES: Arrhythmogenic right ventricular cardiomyopa-
thy (ARVC) is a genetically determined heart muscle disease
associated with arrhythmia, heart failure and sudden death often
being the ﬁrst manifestation in probands. The aim of the study
was to evaluate the costs of diagnosis of the disease in asymp-
tomatic relatives in Poland. METHODS: A total of 239 asymp-
tomatic subjects (mean age 35 yeas, 120 men) belonging to 42
families affected with ARVC were examined between May 2003
and May 2005. The costs of out-patients visit and additional
diagnostic tests were included. Payer perspective was used.
RESULTS: In all individuals electrocardiogram and transthoracic
echocardiography were performed. Magnetic resonance imaging
and signal averaged electrocardiogram were performed in 35
patients suspected of having ARVC. The diagnostic criteria for
ARVC were detected in 29 patients and 57 subjects fulﬁlled the
borderline criteria for ARVC. Total costs of screening amounted
to €13,086.35. The average cost per one case of ARVC detected
was €451.25. CONCLUSIONS: Costs of early detection of
ARVC in individuals with a family history of the disease are low
and enable the family screening in asymptomatic subjects in
Poland.
PCV8
COST OF HOSPITALIZATION FOR PATIENTS WITH
ARRHYTHMOGENIC RIGHT VENTRICULAR
CARDIOMYOPATHY IN POLAND
Kowalik E, Glinka M,Wlodarska EK,Wozniak O, Hoffman P
Institute of Cardiology, Warsaw, Poland
OBJECTIVES: Arrhythmogenic right ventricular cardiomyopa-
thy (ARVC) is a progressive heart muscle disease characterized
by replacement of right ventricular myocardium by ﬁbrofatty
tissue and resulting in life threatening ventricular arrhythmias
and heart failure. The aim of the study was to evaluate costs of
hospital care in cardiology department for patients with ARVC
in Poland. METHODS: Data on resource utilization were col-
lected prospectively in patients with ARVC hospitalized in the
tertiary center from May 2003 to May 2005. Patients’ stay ﬁxed
costs, costs of additional tests and procedures were extracted
from hospital sources. Payer perspective was used. RESULTS: A
group of 39 patients with mean age 41.4 years (56% male) was
analyzed. Average length of stay in the cardiologic department
was 13.4 days (ranging from 2 to 76 days). Total costs of hos-
pital care amounted to €191,029.90. Average cost per patient
was €4898.20. Procedural costs represented the major cost item
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(71.2%) followed by cost of hospital stay (21.8%) and diag-
nostic costs (7%). Costs of hospital care for patients with ven-
tricular arrhythmias were signiﬁcantly higher as compared to
patients with heart failure (€5890.82 and €1959.35, respec-
tively). CONCLUSIONS: This study demonstrates that ARVC is
associated with high hospitalization costs in Poland, mainly due
to large costs of antiarrhythmic procedures.
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THE EFFECT OF ANTICOAGULATION FOR STROKE
PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION—
COMPARING EFFICACY AND EFFECTIVENESS
Dewilde S1, Sorensen SV2, Brown R3, Monz BU4
1The MEDTAP Institute at UBC, Brussels, Belgium; 2The MEDTAP
Institute at UBC, Bethesda, MD, USA; 3MedTap Institute at UBC,
London, UK; 4Boehringer Ingelheim, Ingelheim, Germany
OBJECTIVES: To investigate different scenarios of warfarin
treatment for patients with non-valvular atrial ﬁbrillation who
are eligible to receive anticoagulation for stroke prevention. Sce-
narios include different proportions of eligible patients being
treated, as well as the level of anticoagulation obtained (i.e.
within and outside the recommended INR range). METHODS:
A decision-analytical model was constructed from a third party
payer perspective for the US. The model runs for ﬁve years in
yearly cycles. Strokes (fatal, major, minor and no deﬁcit) and
bleeding events (fatal, intracranial, major and minor) were
modeled. Probabilities and costs associated with events were
taken from published sources. Four scenarios were compared:
1). 100% of eligible patients warfarin treated and all within the
therapeutic range; 2). 100% of eligible patients’ warfarin treated
whereof 67% within and 33% outside the therapeutic range
(randomized controlled trial-like); 3). 100% of eligible patients
warfarin treated whereof 50% within/outside the therapeutic
range (routine practice INR levels); and 4). 55% warfarin treated
(of whom 50% within/outside recommended INR range), 5% no
treatment, and 40% aspirin (routine practice for warfarin treat-
ment rates and INR levels). RESULTS: At 5 years, total costs per
patient (discounted at 3%) and the total number of strokes per
1000 patients (discounted at 3%) were for strategy 1: $8607 and
25, for strategy 2: $12,518 and 46, for strategy 3: $14,582 and
58, and for strategy 4: $15,480 and 129, respectively. CON-
CLUSIONS: In a real world setting, evidence demonstrates that
patient’s eligible for anticoagulation may not be treated, and
those treated with warfarin may not be in the therapeutic range
for anticoagulation. This will lead to marked differences between
the observed efﬁcacy and effectiveness as demonstrated for the
number of strokes and costs in this model. This will need to be
addressed in any cost-effectiveness analysis using warfarin as
comparator.
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DRIVERS OF UNDERUSE OF VITAMIN K ANTAGONISTS IN
PATIENTS WITH CHRONIC NONVALVULAR ATRIAL
FIBRILLATION IN FRANCE: THE ENSEFAL STUDY
Guenoun M1, Le Jeunne P2, Lamarque H3
1Clinique Bouchard, Marseille, France; 2BKL-Thales, Boulogne
Billancourt, France; 3AstraZeneca France, Rueil-Malmaison, France
OBJECTIVES: Describe prevalence and characteristics of
patients with chronic nonvalvular atrial ﬁbrillation (NVAF) and
≥1 risk factor (RF) for thromboembolism in France in 2004, and
document reasons for vitamin K antagonists (VKA) underuse 
in those patients for whom anticoagulation is indicated.
METHODS: Cross sectional study. All patients with arrhythmia
or AF presenting to cardiologists (n = 43) from the THALES
observatory during a 3-month period were evaluated via ques-
tionnaire. Statistical comparisons were by chi2 and ANOVA
analyses. Data were extrapolated using the THALES database to
give representative national values. RESULTS: 409 patients met
the inclusion criteria, i.e., conﬁrmed NVAF and ≥1 thromboem-
bolic RF (mean age 76 years; mean number of thromboembolic
RF 2.11; 58.7% male). Of these, 37.2% had 1 RF, 28.9% had
2 RF and 34.0% had ≥3 RF. VKA was prescribed to 65.5% of
patients. VKA treatment was associated with a higher mean
number of RF (2.28) than aspirin (2.20) or no treatment (1.61).
Among VKA-treated patients, 18.6% were judged difﬁcult to
stabilise/not stabilised by the physician. Main reasons for not
prescribing VKA were insufﬁcient risk: beneﬁt (37.6%), patient’s
refusal due to VKA restrictions (23.4%) and patient’s inherent
haemorrhagic risk (19.1%). According to anticoagulation exclu-
sion criteria (severe hepatic insufﬁciency, recent stroke, and
patient’s inherent haemorrhagic risk) most patients not treated
with VKA (77.3%) would have been eligible for anticoagulation.
Extrapolation of these ﬁndings to the French population equated
to 426,731 (95% CI 420,099–433,363) patients with chronic
NVAF. Of these, 147,124 (34.5%) would not be treated with
VKA, even though 113,719 would have been eligible for anti-
coagulation. CONCLUSIONS: These data suggest that one 
third of French patients with chronic NVAF and ≥1 throm-
boembolic RF presenting to cardiologists are currently not
treated with VKA. Main drivers for this non-prescription are
more related to risk and constraints of VKA treatment than
formal contraindications.
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ANTICOAGULATION IN PATIENTS WITH NON-VALVULAR
ATRIAL FIBRILLATION: AN EVALUATION OF STABILITY AND
EARLY FACTORS THAT PREDICT LONGER-TERM STABILITY
ON WARFARIN IN A LARGE UK POPULATION
Currie CJ1, McEwan P2, Emmas C3, Peters JR4
1Cardiff University, Cardiff, UK; 2Cardiff University, Cardiff, Wales, UK;
3AstraZeneca-UK, Luton, Bedfordshire, UK; 4University Hospital of
Wales, Cardiff, UK
OBJECTIVES: To determine the proportion of patients with
non-valvular atrial ﬁbrillation (NVAF) treated with warfarin that
achieved INR stability. To then evaluate the associations between
stability and outcome, and factors that predict stability.
METHODS: A retrospective record linkage study in 1513
patients with NVAF treated with warfarin for a minimum of six
months. The setting was a large UK population (ª450,000
people). The main outcome measures were stability deﬁned as
six consecutive months within the target INR range (2.0–3.0),
thromboembolic and bleeding event rates, and mortality. Sec-
ondary outcome measures included the predictive value of base-
line characteristics and other treatment variables. RESULTS:
Stability was achieved in 52% of the study group. Standardised
mean survival was signiﬁcantly higher in the group who achieved
stability (D = 16.9 months, p < 0.001) with a hazard ratio of 4.36
(p < 0.001). The stable group had a lower rate of both throm-
boembolic events (0.8% vs. 2.3% per patient year) and major
bleeds (0.4% vs. 1.2% per patient year). Failure to achieve 
stability was associated with age (odds ratio 1.01 (95% CI
1.001–1.021)) and morbidity at baseline (OR 1.015; 95% CI
1.007–1.022). Greater variability in INR was also associated
with a failure to achieve stability (OR 1.518; 95% CI
1.427–1.615). Receiver operator characteristic (ROC) analysis
using data from the ﬁrst three month of treatment demonstrated
good discrimination of stability using age and morbidity at base-
line and percent time in range and frequency of visits during ﬁrst
three months treatment (AUC 0.780; SE 0.012; 95% CI
0.757–0.803). CONCLUSIONS: Many patients never achieved
